Modulation of therapeutic antibody effector functions by glycosylation engineering: Influence of Golgi enzyme localization domain and co‐expression of heterologous β1, 4‐N‐acetylglucosaminyltransferase III and Golgi α‐mannosidase II
暂无分享,去创建一个
Samuel Moser | Tobias Suter | Ursula Püntener | P. Umaña | C. Ferrara | P. Brünker | T. Suter | S. Moser | U. Püntener | Claudia Ferrara | Peter Brünker | Pablo Umaña
[1] R. Dwek,et al. Variations in oligosaccharide-protein interactions in immunoglobulin G determine the site-specific glycosylation profiles and modulate the dynamic motion of the Fc oligosaccharides. , 1997, Biochemistry.
[2] M J Keen,et al. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. , 1995, Glycobiology.
[3] S L Morrison,et al. Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. , 1989, Journal of immunology.
[4] G. Warren,et al. The role of the membrane-spanning domain and stalk region of N-acetylglucosaminyltransferase I in retention, kin recognition and structural maintenance of the Golgi apparatus in HeLa cells. , 1996, Journal of cell science.
[5] Leonard G. Presta,et al. Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.
[6] P. Carter,et al. Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.
[7] Leonard G. Presta,et al. High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.
[8] J. Baars,et al. Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.
[9] K. Shitara,et al. The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.
[10] Naoyuki Taniguchi,et al. A catalytically inactive beta 1,4-N-acetylglucosaminyltransferase III (GnT-III) behaves as a dominant negative GnT-III inhibitor. , 2002, European journal of biochemistry.
[11] J. Rothman,et al. Attachment of terminal N-acetylglucosamine to asparagine-linked oligosaccharides occurs in central cisternae of the golgi stack , 1985, Cell.
[12] M. Farquhar,et al. Cell type-dependent variations in the subcellular distribution of alpha- mannosidase I and II , 1993, The Journal of cell biology.
[13] D. Roos,et al. FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .
[14] L. Presta,et al. Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.
[15] R. Huber,et al. Crystallographic structure studies of an IgG molecule and an Fc fragment , 1976, Nature.
[16] H. Schachter,et al. Biosynthetic controls that determine the branching and microheterogeneity of protein-bound oligosaccharides. , 1986, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[17] V. Diehl,et al. CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .
[18] S L Morrison,et al. Effect of glycosylation on antibody function: implications for genetic engineering. , 1997, Trends in biotechnology.
[19] James E. Bailey,et al. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.
[20] J. Briggs,et al. Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.
[21] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[22] G. Winter,et al. The binding site for C1q on IgG , 1988, Nature.
[23] J. Briggs,et al. A high-throughput microscale method to release N-linked oligosaccharides from glycoproteins for matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analysis. , 1998, Glycobiology.
[24] P. Colombat,et al. Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.
[25] A. Gambotto,et al. Identification of the CD32/FcgammaRIIc-Q13/STP13 polymorphism using an allele-specific restriction enzyme digestion assay. , 2001, Journal of immunological methods.
[26] G. Salles,et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.
[27] T Nilsson,et al. Mapping the distribution of Golgi enzymes involved in the construction of complex oligosaccharides. , 1995, Journal of cell science.
[28] P. Gleeson,et al. Medial Golgi but Not Late Golgi Glycosyltransferases Exist as High Molecular Weight Complexes , 2000, The Journal of Biological Chemistry.
[29] S L Morrison,et al. Effect of altered CH2-associated carbohydrate structure on the functional properties and in vivo fate of chimeric mouse-human immunoglobulin G1 , 1994, The Journal of experimental medicine.
[30] R. Jefferis,et al. IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation , 1998, Immunological reviews.
[31] F. Wurm,et al. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. , 1996, Nucleic acids research.
[32] M. Takeuchi,et al. The Widespread Effect of β1,4-Galactosyltransferase on N-Glycan Processing , 2001 .